

PRESS RELEASE

22 December 2021 15:00:00 CET

Senzime recruits new CFO

Press release: Uppsala 22 of December 2021. Senzime AB (publ) announces today that the company's CFO Erik Bergman will retire and hand over to Slavoljub Grujicic who will take over as the company's CFO during the first quarter of 2022.

Erik Bergman took over as CFO in 2019 and will remain in the company for a transitional period until the end of the second quarter.

As his successor, the company has today appointed Slavoljub Grujicic as the new CFO. Slavoljub has extensive experience from various financial roles in large international groups within MedTech. He most recently comes from a position as Senior Business Analyst at Becton Dickinson & Company. Slavoljub will assume the position as CFO during the first quarter of 2022.

"Erik has been a very valuable member of the management team and has played a central role in development projects such as the implementation of IFRS, the establishment of subsidiaries and the change of list to Nasdaq Stockholm. I wish him great luck in the future with more time for his grandchildren in combination with his own consulting business. Slavoljub enters an extremely exciting commercial phase where his analytical skills and experience as a controller will be important for our continued expansion", says Pia Renaudin, CEO of Senzime.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB
Phone: +46 (0) 70-813 34 17, email: pia.renaudin@senzime.com

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq Stockholm's main market (ticker SEZI) since June, 30 2021. www.senzime.com

Attachments

Senzime recruits new CFO